Thyrocare Technologies Limited has informed the exchange regarding submission of machine-readable document of earlier submitted results of the Company for the quarter ended on June 30, 2026

0 Thyrocare Tests you can trust July 24, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers B(SaYnMdrBaO KLu:r TlaH CYoRmOpCleAxR, E ) D(SaClaRlI SPt rCeOeDt, E: 539871) Bandra (E), Mumbai - 400051 Mumbai- 400001 Subject: Resubmission of Unaudited Financial Results (Standalone & Consolidated) for the Quarter Ended June 30, 2026, in Machine-Readable Format/Legible copy Dear Sir/Madam, This is with reference to the email dated July 24, 2026, received from the National Stock Exchange of India Limited (NSE) regarding submission of financial results for the period ended June 30, 2026, in Machine Readable Form / Legible copy pursuant to NSE Circular No. NSE/CML/2018/02 dated January 16, 2018. We wish to inform you that the Company had already submitted the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the respective Limited Review Reports, pursuant to the outcome of the Board Meeting held on July 23, 2026. Pursuant to the aforesaid NSE Circular and in compliance with the email received from NSE, we are hereby resubmitting the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, together with the respective Limited Review Reports, in machine-readable / legible copy for your records. Kindly take the same on record. Thyrocare Technologies Limited, Yours Faithfully, Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a Thyrocare Technologies Limited 9 D-37/1, TTC MIDC, Turbhe, Navi Mumbai-400 703, India (9 022-3090 0000 ~ enquiry@thyrocare.com (@www.thyrocare.com Price Waterhouse Chartered Accountants LLP Review Report The Board of Directors Thyrocare Technologies Limited D-3711, MIDC, Turbhe, Opp. Sandoz, Navi Mumbai -400 703. 1. We have reviewed the unaudited standalone financial results of Thyrocare Technologies Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying 'Unaudited Standalone Financial Results for the Quarter ended June 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants oflndia. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. \lse Ch:i Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai - 400 028 T: +91(22) 66697510 Registered office and Head office: I I-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi. 110 002 ~rice_W aterhouse (a Partnership Finn) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP 1de?llty ~o: LLPIN AAC-5001) with effect from July 25, 2014. Post its Conversion to Price Waterhouse Chartered Accountants LLP, its ICAI reg1strat1on number is 012754N/N500016 (!CAI registration number before conversion was 012754N) Price Waterhouse Chartered Accountants LLP 5. (a) The standalone financial results of the Company for the quarter ended June 30, 2025 were reviewed by another firm of chartered accountants who issued their unmodified conclusion, vide their report dated July 23, 2025. (b) The standalone financial statements of the Company for the year ended March 31, 2026 were audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated May 07, 2026. Our conclusion is not modified in respect of these matters. For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016 Nitin Khatri Partner Membership Number: 110282 UDIN: 26110282PLRUZK1897 Place: Mumbai Date: July 23, 2026. THYROCARE TECHNOLOGIES LIMITED Registered Office: D/37-1, TIC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703 Corporate Office: D/37-3, TIC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703 Tel: (91 22) 2762 2762 I Fax: (91 22) 2768 2409 Website: www.thyrocare.com E-mail: kumar.b rijesh@thyrocare.com Corporate Identity Number: L8S 11 0MH2000PLC 123882 Unaudited Standalone Financial Results for the Quarter ended June 30, 2026 (Rs. in Crores) Quarter ended March 31, 2026 Sr. No Particulars June 30, 2026 March 31, 2026 June 30, 2025 (Audited) (Unaudited) (Unaudited) (Unaudited) Refer Note 2 l Revenue (a) Revenue from operations 225.66 210.67 178.89 774.27 (b) Other Income 3.51 3.72 3.96 13.39 Total Reveue (a+b) 229.17 214.39 182.85 787.66 2 Expenses (a) Cost of materials consumed 58.86 54.27 52.37 208.37 (b) Purchase of stock-in-trade O.o3 0.77 0.07 1.09 (c) Changes in inventories of finished goods, work-in-progress 0.24 (0.51) 0.1S (0.23) and stock-in-trade (d) Employee benefits expense 37.16 33.44 30.70 128.29 (e) Finance cost 1.26 1.43 0.62 2.18 (f) Depreciation and amortisation expense 11.23 12.94 8.95 51.17 (g) Other expenses 53.76 S0.07 39.08 180.42 Total Expenses 162.54 152.41 131.94 571.29 3 Profit before exceptional items and income tax (I -2) 66.63 61.98 50.91 216.37 - - - 4 Exceptional Items 5.97 5 Profit after exceptional items and before tax (3 -4) 66.63 61.98 50.91 210.40 6 Tax expense (16.46) (18.40) (14.86) (61.59) 7 Profit for the period/year (5 + 6) 50.17 43.58 36.05 148.81 8 Other comprehensive income Items that will not be reclassified to profit or loss (net of tax) 0.48 0.48 (0.21) 0.22 9 Total comprehensive income for the period/ year (7 + 8) 50.65 44.06 35.84 149.03 Paid-up equity share capital (Face value of Rs. I 0/-each) 159.17 159.17 52.99 159.17 Other equity 401.51 10 Earnings per share (of Rs. 10/-each): (a) Basic (in Rs.) 3.15* 2.75* 2.27* 9.36 (b) Diluted (in Rs.) 3.14* 2.75* 2.26* 9.34 *not annualised See accompanying notes to the Standalone Financial Results Notes: 1 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 23 July 2026 and subsequently approved by the Board of Directors at its meeting held on 23 July 2026. The statutory auditors of the Company have expressed an unmodified conclusion [Showing first 8,000 characters — download PDF for full document]